AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL) Stock Price, Analysis & Data
| Precio de compra | 7.23 |
| Capitalización de mercado | 3.1B |
| Ingresos (TTM) | 66.17M |
| Beneficio neto (TTM) | -164.66M |
| Beta | 1.19 |
| EPS (TTM) | -0.54 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -14.14 |
| P/B (TTM) | 3.46 |
| P/S (TTM) | 46.85 |
| Earnings Date | Nov 5, 2026 |
| Precio de venta | 11.54 |
| Volumen | 8,339,607 |
| Volumen medio (20D) | 7,727,175 |
| Abierto | 9.25 |
| Anterior Cerrar | 9.76 |
| Rango del día | 9.00 - 10.20 |
| Rango de 52 semanas | 2.75 - 10.29 |
| analista | Strong Buy |
| Precio objetivo | 15 (48.37%) |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, su...
Desempeño financiero
En 2025, los ingresos de AbCellera Biologics fueron 75.13M, un aumento de 160.56% en comparación con 28.83M del año anterior. Las ganancias fueron -146.41M, una disminución de -10.1%.
Estados financierosPronóstico del analista
Según las calificaciones de los analistas de 8, la calificación promedio de las acciones de ABCL es "Strong Buy". El pronóstico del precio de las acciones a 12 meses es 15, que es Potencial alcista de 48.37% del último precio.
Previsiones bursátilesSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
15 horas hace · Simply Wall St.
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 ResultsWhy ABCL635’s Phase 2 data matters for AbCellera Biologics stock AbCellera Biologics (ABCL) has become a focus for many biotech investors after announcing that ABCL635 met primary endpoints in a Phase...
21 horas hace · Simply Wall St.
AbCellera Biologics (ABCL) Gets Its First Pipeline Win With Positive Phase 2 DataAbCellera Biologics (NasdaqGS:ABCL) reports positive top line Phase 2 results for ABCL635, its non hormonal antibody treatment for moderate to severe menopausal vasomotor symptoms. The trial shows cli...